Date:	Jan. 4 ^{tt}	¹ , 2022			
Your	Name:	Hyeok Jun Goh			
Manu	script Title	: Efficacy of Phosphodiesterase Type 5 inhibitors in Patients with Erectile Dysfunction aft	er Nerve-		
<u>sparir</u>	ng Radical F	Prostatectomy: A Systematic Review and Meta-analysis			
Manuscript number (if known): TAU-21-881					

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	The Bio & Medical Technology Development Program of the National Research Foundation and the Korean government (Ministry of Science and ICT) [NRF- 2019M3E5D1A01069353].	The funder had no role in this study.
		Time frame: past	36 months
2		XNone	

		I	T
	Grants or contracts from any entity (if not indicated in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	X None	
·	consum rees		
5	Payment or honoraria for	X None	
3	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
	•		
7	Support for attending	X None	
	meetings and/or travel		
	g ,		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

I have no above conflicts of interest to declare except the funding, of which the funders had no role i	n this study.

Please place an "X" next to the following statement to indicate your agreement:				
X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.				

Date:_	Jan. 4 th , 2022	

Your Name: <u>Jeong Min Sung</u>

Manuscript Title: Efficacy of Phosphodiesterase Type 5 inhibitors in Patients with Erectile Dysfunction after Nerve-

sparing Radical Prostatectomy: A Systematic Review and Meta-analysis

Manuscript number (if known): TAU-21-881

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	The Bio & Medical Technology Development Program of the National Research Foundation and the Korean government (Ministry of Science and ICT) [NRF- 2019M3E5D1A01069353].	The funder had no role in this study.
		Time frame: past	36 months
2		XNone	

	Grants or contracts from any entity (if not indicated in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	X_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	

I have no above conflicts	s of interest to declare except the funding, of which the funders had no role in this study.

Please place an "X" next to the following statement to indicate your agreement:				
X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.				

Date: Jan. 4th, 2022

Your Name: Kwang Hyun Lee

Manuscript Title: Efficacy of Phosphodiesterase Type 5 inhibitors in Patients with Erectile Dysfunction after Nerve-

sparing Radical Prostatectomy: A Systematic Review and Meta-analysis

Manuscript number (if known): TAU-21-881

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. The Bio & Medical Technology Development Program of the National Research Foundation and the Korean government (Ministry of Science and ICT) [NRF-2019M3E5D1A01069353].			Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	The Bio & Medical Technology Development Program of the National Research Foundation and the Korean government (Ministry of Science and ICT) [NRF-	
Time frame: past 36 months X None	2			36 months

	Grants or contracts from any entity (if not indicated in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	X_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	

I have no above conflicts of interest to declare except the funding, of which the funders had no role in this study.

Please place an "X" next to the following statement to indicate your agreement:
X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	Jan. 4 th ,	2022	
Your Nar	me:	Jung Ki Jo	

Manuscript Title: Efficacy of Phosphodiesterase Type 5 inhibitors in Patients with Erectile Dysfunction after Nerve-

sparing Radical Prostatectomy: A Systematic Review and Meta-analysis

Manuscript number (if known): TAU-21-881

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial The Bio & Medical Technology Development Program of the National Research Foundation and the Korean government (Ministry of Science and ICT) [NRF- 2019M3E5D1A01069353].	The funder had no role in this study.
		Time frame: past	36 months
2		XNone	

	Grants or contracts from any entity (if not indicated in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	X_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	

I have no above conflicts of interest to declare except the funding, of which the funders had no role in this study.

Please place an "X" next to the following statement to indicate your agreement:
X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: Jan. 4th, 2022

Your Name: Kyu Nam Kim

Manuscript Title: Efficacy of Phosphodiesterase Type 5 inhibitors in Patients with Erectile Dysfunction after Nerve-

sparing Radical Prostatectomy: A Systematic Review and Meta-analysis

Manuscript number (if known): TAU-21-881

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	The Bio & Medical Technology Development Program of the National Research Foundation and the Korean government (Ministry of Science and ICT) [NRF- 2019M3E5D1A01069353].	The funder had no role in this study.
		Time frame: past	36 months
2		XNone	

	Grants or contracts from any entity (if not indicated in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	X_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	

I have no above conflicts of interest to declare except the funding, of which the funders had no role in this study.

Please place an "X" next to the following statement to indicate your agreement:
X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.